Savara Inc.
NASDAQ:SVRABiotechnology
+$0.03 today
- Market cap
- $1.04B
- Beta
- 0.27
- P/E (TTM)
- -10.6
- EPS (TTM)
- -$0.51
Volume 5.51M
Average 1.53M
SVRA Common Stock Issued
Cash raised by issuing new shares.
Savara Inc.NASDAQ: SVRA
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued dips below year-ago levels
Q1 FY2026 common stock issued of $45K fell 72.7% year over year, behind the +18.5% change in trailing-twelve-month common stock issued. Sequentially, it fell 100.0% from the prior quarter.
Context
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -72.7% toward the trailing-twelve-month pace of +18.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 140.23M USD
- Year-over-year change
- +18.7%
- 4-year CAGR
- +3.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 140.23M | +18.7% |
| FY2024 | 2024-12-31 | 118.17M | +41.2% |
| FY2023 | 2023-12-31 | 83.71M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 122.23M | — |
Common Stock Issued vs competitors
How SVRA compares with its peers on the latest reported figures
- SVRA's LTM Mar 2026 common stock issued of $140.5M is the largest of the 2 companies compared; the peer median is $1.01M.
- Its year-over-year change of +18.5% is the lowest of 2, against a peer median of +746.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $140.5M | +18.5% | — | — | |
| LTM Mar 2026 | $1.01M | +746.2% | — | 0.9% | |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding SVRA) | $1.01M | +746.2% | — | 0.9% | |
Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.01M) | (38.15M) | (54.7M) | (95.88M) | (118.84M) |
| Depreciation & Amortization | 367K | 167K | 77K | 130K | 87K |
| Deferred Income Tax | 1.7M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.26M | 2.04M | 4.18M | 9.86M | 14.42M |
| Change in Working Capital | (2.85M) | 960K | 4.07M | 1.83M | 5M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.76M) | (319K) | 4.54M | 4.2M | 4.81M |
| Other Working Capital | (1.08M) | 1.28M | (468K) | (2.37M) | 195K |
| Other Non-Cash Items | 449K | 428K | (4.69M) | (5.03M) | (1.71M) |
| Operating Cash Flow | (40.08M) | (34.55M) | (51.06M) | (89.09M) | (101.04M) |
| Capital Expenditures | (57K) | (9K) | (296K) | (25K) | (22K) |
| Acquisitions (Net) | (8.2M) | 0 | 56.82K | 0 | 0 |
| Purchases of Investments | (161.07M) | (89.42M) | (194.22M) | (204.92M) | (204.9M) |
| Sales of Investments | 91.67M | 142.07M | 137.4M | 165M | 182.2M |
| Other Investing Activities | 8.2M | 0 | (56.82K) | 0 | 4.28M |
| Investing Cash Flow | (69.46M) | 52.65M | (57.12M) | (39.94M) | (18.44M) |
| Debt Repayment | 0 | 88K | 0 | 0 | 2.37M |
| Common Stock Issued | 122.23M | 0 | 83.71M | 118.17M | 140.23M |
| Common Stock Repurchased | (78K) | (3K) | (1.21M) | (995K) | (5.14M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.35M) | 2K | 0 | 400K | 0 |
| Financing Cash Flow | 120.81M | 87K | 82.78M | 117.58M | 137.81M |
| Effect of Forex Changes | (137K) | (90K) | (118K) | (5K) | (277K) |
| Net Change in Cash | 11.13M | 18.09M | (25.52M) | (11.46M) | 18.05M |
| Free Cash Flow | (40.14M) | (34.56M) | (51.36M) | (89.11M) | (101.06M) |
Savara Inc.
NASDAQ:SVRA
Intrinsic Alpha fair value
Locked
Current Price
$4.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.